Eli Lilly and Company (LLY) will report first-quarter 2024 results on Apr 30, before market open.The Zacks Consensus Estimate for this drug giant’s first-quarter revenues is pegged at $8.81 billion, while the same for earnings per share is $2.53 per share, both indicating significant increases from the year-ago quarter.In the first quarter, top-line growth is expected to have been driven by strong demand for Lilly’s new tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. The Za ...

The market expects Eli Lilly (LLY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

The most recent trading session ended with Eli Lilly (LLY) standing at $731.33, reflecting a +0.69% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.87% gain on the day. Meanwhile, the Dow gained 0.67%, and the Nasdaq, a tech-heavy index, added 1.11%.Prior to today's trading, shares of the drugmaker had lost 5.75% over the past month. This has was narrower than the Medical sector's loss of 6.67% and lagged the S&P 500's loss of 3.97% in that time.The investment community wi ...

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.Eli Lilly and Novo Nordisk are two of the biggest names in healthcare thanks in large part to some promising weight-loss drugs in their respective portfolios. In the past 12 months, Eli Lilly has doubled in value, while Novo Nordisk's stock is up around 50%. Those who haven't invested in these stocks may be inclined to pass on them given their high valuations now -- both are worth more than $500 billion.There are other ways to invest i ...

In this articleMSNOVO.B-DKLLYA food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023.Jeenah Moon | The Washington Post | Getty ImagesA highly popular group of weight loss and diabetes drugs is decreasing some consumers' appetites — and also how much they spend on food.Most people taking those medications, called GLP-1s, say they are spending less on eating out at restaurants and ordering takeout, according to a Morgan Stanley survey released on Tuesday. A smal ...

Low risk and high-reward potential? These stocks could offer both.No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects.Three Motley Fool contributors think they've found relatively safe growth stocks you can buy and hold. Here's why they picked Eli Lilly (LLY -2.63%), Novo Nordisk (NVO -0.03%), and Vertex Pharmaceuticals (VRTX 0.20%).Closing in on a trillion-dollar valuationProsper Junior Bakiny (Eli Lilly): Many ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Eli Lilly and Company (LLY) announced that its pipeline candidate, tirzepatide, met all primary and key secondary endpoints in two phase III studies evaluating it in adults with obstructive sleep apnea (OSA) and obesity.OSA is a common sleep-related breathing disorder that causes repeated interruptions in breathing during sleep. This can lead to decreased oxygen levels in the blood, causing strain on the cardiovascular system and other organs over time. It can lead to complications like hypertension, corona ...

These stocks have taken different paths to where they are today, but both have been exceptional investments.Think 10 years is not enough time to significantly grow your portfolio? Let's look at a couple of examples where investing $10,000 would have been enough to get your portfolio to more than six figures in a decade. Of course, these examples don't imply that things always pan out this way. There are plenty of examples of stocks that lose money over time too. But investing with a long-term mindset can pa ...

Key TakeawaysEli Lilly on Wednesday said its weight-loss treatment, Zepbound, was successful in helping patients with obstructive sleep apnea (OSA).A Phase 3 trial found on average Zepbound reduced the number of sleep-apnea events by up to 63%.The drug maker plans to ask the Food and Drug Administration (FDA) and other regulators to expand the use of Zepbound for OSA by mid-year. Shares of Eli Lilly (LLY) gained in intraday trading Wednesday after the pharmaceutical firm said a late-stage study found its we ...